We read with interest the recent report in Hypertension from Martin et al 1 on the effects of intra-arterial administration of the endothelin ET A/B receptor antagonist, SB 209670, on forearm blood flow in hypertensive subjects and matched controls. Their finding of forearm vasodilation to intra-arterial SB 209670 in healthy controls suggests a role for endothelin-1 (ET-1) in regulation of basal vascular tone and is consistent with our own work [2] [3] [4] and that of some, 4, 5 but not all other groups, 6,7 with both ET A receptor selective and ET A/B receptor antagonists. Also, contrary to some earlier work, 6,7 they find no difference from controls in the in vivo response of the resistance vessels of hypertensive subjects to ET receptor antagonism.
Response
We thank Doctors Goddard and Webb for their comments regarding intra-arterial infusion of endothelin (ET) antagonists. Goddard and Webb raise a number of relevant issues. They reiterate the importance of using subsystemic doses of vasoactive substances to test hypotheses regarding direct effects on the vasculature. The key issue is how to establish that doses are indeed subsystemic. The usual approach includes careful assessment of systemic blood pressure and heart rate responses and/or measurement of forearm blood flow and vascular resistance in the contralateral limb. 1 This is really a general issue of the technique itself and not limited to endothelin blockade as the vasoactive substance.
Specific to endothelin blockade, however, is the issue of selectivity of the receptor antagonist. Goddard and Webb suggest that doses of the ET A -"selective" antagonist BQ-123, assumed to be subsystemic in a number of studies, 2,3 may indeed be systemically active 4 and also block ET B -mediated vasodilation. 5 However, this still does not explain differences in vascular responses to this agent given at the same dose and at the same infusion rate over similar periods of time. We used SB209670 in our study 6 specifically because it is nonselective, and we wished to test the impact of blockade of all major ET receptor subtypes on the vasculature, between normal subjects and patients with cardiovascular disease. 
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